Ignacio Muñoz-Sanjuán, Ph.D.
Ignacio is Chief Executive Officer at Rumi Scientific. Ignacio brings over 21 years of dedicated experience in neurodegeneration research and development from his time at Merck, Amgen, and the CHDI Foundation, where he was Vice President of Translational Biology. At CHDI, Ignacio oversaw the development of numerous programs in Huntington’s Disease (HD) across small molecules, antisense oligonucleotides (ASOs), protein degraders, and gene therapies. He developed the first small molecule PET imaging ligands for mutant Huntingtin and has extensive experience in biomarker development, including imaging, neurophysiological, and proteomics approaches, which are widely used in current HD clinical trials. Ignacio became the CEO of Cajal Neuroscience in his first experience leading a biotech organization. Ignacio founded and currently serves as President of the Factor-H Foundation, a non-profit organization committed to improving the quality of life of patients suffering from HD in Latin America.
Ignacio received his PhD from Johns Hopkins University School of Medicine and completed his postdoctoral training at The Rockefeller University. He has authored over 100 research publications and book chapters and is widely regarded as a leading voice in HD research and advocacy, having been recognized with the 2024 Public Service Award from the International Movement Disorder Society.